|
1
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et
al: Neoadjuvant chemotherapy for osteosarcoma of the extremities
with metastases at presentation: Recent experience at the Rizzoli
Institute in 57 patients treated with cisplatin, doxorubicin, and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kimura K, Nakano T, Park YB, Tani M, Tsuda
H, Beppu Y, Moriya H and Yokota J: Establishment of human
osteosarcoma cell lines with high metastatic potential to lungs and
their utilities for therapeutic studies on metastatic osteosarcoma.
Clin Exp Metastasis. 19:477–485. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morishita T, Mii Y, Miyauchi Y, Miura S,
Honoki K, Aoki M, Kido A, Tamai S, Tsutsumi M and Konishi Y:
Efficacy of CDDP and AGM-1470 chemotherapy against lung metastasis
in rat osteosarcoma depends on the timing of combined
administration. Jpn J Clin Oncol. 27:236–239. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Whelan J, Seddon B and Perisoglou M:
Management of osteosarcoma. Curr Treat Options Oncol. 7:444–455.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Meng W and Cui H: LncRNA CBR3-AS1
predicts unfavorable prognosis and promotes tumorigenesis in
osteosarcoma. Biomed Pharmacother. 102:169–174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu D, Nie X, Ma C, Liu X, Liang X, An Y,
Zhao B and Wu X: RSF1 functions as an oncogene in osteosarcoma and
is regulated by XIST/miR-193a-3p axis. Biomed Pharmacother.
95:207–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng DD, Li SJ, Zhu B, Zhou SM and Yang
QC: EEF1D overexpression promotes osteosarcoma cell proliferation
by facilitating Akt-mTOR and Akt-bad signaling. J Exp Clin Cancer
Res. 37:502018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and its crosstalk with other
cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang C: Novel functions for small RNA
molecules. Curr Opin Mol Ther. 11:641–651. 2009.PubMed/NCBI
|
|
15
|
Li Y, Liu J, Liu ZZ and Wei WB:
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma
by targeting cyclin-dependent kinase, CDK6. Eur Rev Med Pharmacol
Sci. 20:5117–5125. 2016.PubMed/NCBI
|
|
16
|
Wang X, Lin Y, Peng L, Sun R, Gong X, Du J
and Zhang X: MicroRNA-103 promotes proliferation and inhibits
apoptosis in spinal osteosarcoma cells by targeting p57. Oncol Res.
26:933–940. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nan YH, Wang J, Wang Y, Sun PH, Han YP,
Fan L, Wang KC, Shen FJ and Wang WH: MiR-4295 promotes cell growth
in bladder cancer by targeting BTG1. Am J Transl Res. 8:4892–4901.
2016.PubMed/NCBI
|
|
18
|
Zhao F, Yang X, Xu G, Bi J, Lv R and Huo
R: Propranolol suppresses HUVEC viability, migration, VEGF
expression, and promotes apoptosis by downregulation of miR-4295. J
Cell Biochem. 120:6614–6623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Zheng J, Diao H and Liu Y: RUNX3 is
down-regulated in glioma by Myc-regulated miR-4295. J Cell Mol Med.
20:518–525. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan Q, Zhang Y, Li J, Cao G and Yang W:
High expression of microRNA-4295 contributes to cell proliferation
and invasion of pancreatic ductal adenocarcinoma by the
down-regulation of Glypican-5. Biochem Biophys Res Commun.
497:73–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ivashkiv LB and Donlin LT: Regulation of
type I interferon responses. Nat Rev Immunol. 14:36–49. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eckhardt I, Weigert A and Fulda S:
Identification of IRF1 as critical dual regulator of Smac
mimetic-induced apoptosis and inflammatory cytokine response. Cell
Death Dis. 5:e15622014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alessandro R and Nicole MC: Genome-wide
Identification of IRF1 binding sites reveals extensive occupancy at
cell death associated genes. J Carcinog Mutagen. S6–S009.
2013.PubMed/NCBI
|
|
24
|
Armstrong MJ, Stang MT, Liu Y, Gao J, Ren
B, Zuckerbraun BS, Mahidhara RS, Xing Q, Pizzoferrato E and Yim JH:
Interferon regulatory factor 1 (IRF-1) induces p21WAF1/CIP1
dependent cell cycle arrest and p21WAF1/CIP1 independent modulation
of survivin in cancer cells. Cancer Lett. 319:56–65. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Misaghi A, Goldin A, Awad M and Kulidjian
AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S, Zhang T, Xu W, Ding J, Yin F, Xu J,
Sun W, Wang H, Sun M, Cai Z and Hua Y: Sarcoma-targeting
peptide-decorated polypeptide nanogel intracellularly delivers
shikonin for upregulated osteosarcoma necroptosis and diminished
pulmonary metastasis. Theranostics. 8:1361–1375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu J, Wang H, Hu Y, Zhang YS, Wen L, Yin
F, Wang Z, Zhang Y, Li S, Miao Y, et al: Inhibition of CaMKIIα
activity enhances antitumor effect of fullerene C60 nanocrystals by
suppression of autophagic degradation. Adv Sci (Weinh).
6:18012332019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Collins M, Wilhelm M, Conyers R, Herschtal
A, Whelan J, Bielack S, Kager L, Kühne T, Sydes M, Gelderblom H, et
al: Benefits and adverse events in younger versus older patients
receiving neoadjuvant chemotherapy for osteosarcoma: Findings from
a meta-analysis. J Clin Oncol. 31:2303–2312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hutanu D, Popescu R, Stefanescu H, Pirtea
L, Candea A, Sarau C, Boruga O, Mehdi L, Ciuca I and Tanasescu S:
The molecular genetic expression as a novel biomarker in the
evaluation and monitoring of patients with osteosarcoma-subtype
bone cancer disease. Biochem Genet. 55:291–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang G, Nishimoto K, Yang Y and
Kleinerman ES: Participation of the Fas/FasL signaling pathway and
the lung microenvironment in the development of osteosarcoma lung
metastases. Adv Exp Med Biol. 804:203–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X and Zhang Y: Lycium barbarum
polysaccharides alleviate hydrogen peroxide-induced injury by
up-regulation of miR-4295 in human trabecular meshwork cells. Exp
Mol Pathol. 106:109–115. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin H, Xu J, Guo X, Huang H, Li J, Peng M,
Zhu J, Tian Z, Wu XR, Tang MS and Huang C: XIAP RING domain
mediates miR-4295 expression and subsequently inhibiting p63α
protein translation and promoting transformation of bladder
epithelial cells. Oncotarget. 7:56540–56557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thygesen SJ and Stacey KJ: IRF1 and IRF2
regulate the non-canonical inflammasome. EMBO Rep. 20:e488912019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wan P, Zhang J, Du Q and Geller DA: The
clinical significance and biological function of interferon
regulatory factor 1 in cholangiocarcinoma. Biomed Pharmacother.
97:771–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pavan S, Olivero M, Corà D and Di Renzo
MF: IRF-1 expression is induced by cisplatin in ovarian cancer
cells and limits drug effectiveness. Eur J Cancer. 49:964–973.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lorenzi S, Forloni M, Cifaldi L, Antonucci
C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der
Bruggen P, et al: IRF1 and NF-kB restore MHC class I-restricted
tumor antigen processing and presentation to cytotoxic T cells in
aggressive neuroblastoma. PLoS One. 7:e469282012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pizzoferrato E, Liu Y, Gambotto A,
Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC,
Storkus WJ and Yim JH: Ectopic expression of interferon regulatory
factor-1 promotes human breast cancer cell death and results in
reduced expression of survivin. Cancer Res. 64:8381–8388. 2004.
View Article : Google Scholar : PubMed/NCBI
|
